The U.S. House of Representatives and the Senate have both incorporated the Expanding and Promoting Expertise in Review of Rare Treatments Act (EXPERRT Act), championed by the CF Foundation, as part of a legislative package to reauthorize the U.S. Food and Drug Administration's (FDA) system for evaluating new prescription drugs and devices.
Site Search
206 care center directors sign a letter citing clinical consequences if decision moves forward.
Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.
I was not emotionally prepared the first time I saw my daughter in her vest. But now, I am thankful to have this device as a part of our daily routine to keep her lungs healthy.
The law signals major improvements in health care affordability for people with CF.
Vertex’s copay assistance changes add an undue burden for people living with an already expensive, challenging lifelong disease.
On behalf of the CF community, the Cystic Fibrosis Foundation has expressed its concern to the Social Security Administration (SSA) about a proposed rule that could make it more difficult for people with CF to receive disability benefits.
In an effort led by Congressional Cystic Fibrosis Caucus co-chairs Representatives Edward Markey (D-MA) and Tom Marino (R-PA) and Senator Michael Bennet (D-CO), 37 key members of Congress sent letters to the Social Security Administration (SSA) expressing their concern about a proposed rule that could make it more difficult for people with CF to receive disability benefits.
After more than six years of dedicated service as co-chair of the Congressional Cystic Fibrosis Caucus, Rep. Edward Markey (D-MA) has stepped down from the post as he assumes new responsibilities in the U.S. Senate. Rep. Jim McGovern (D-MA) will replace Markey, joining Rep. Tom Marino (R-PA) as co-chair of the Caucus.